Collegium Pharmaceutical, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Stoughton MA United States (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2012
NCT01685684
First Marketed Drug
2008
tapentadol (nucynta)
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

COLLEGIUM PHARM INC

Active Ingredients

Marketed Drugs (2)

Key: Collegium Pharmaceutical, Inc. (1) Acquired (1)

oxycodone (oxycontin) (2016)

tapentadol (nucynta) (2008)

Drugs in Phase 3 Trials (5)

Key: Collegium Pharmaceutical, Inc. (0) Acquired (5)

buprenorphine (11 trials)

en3409 (1 trial)

fentanyl (Innovar) (3 trials)

naloxone (narcan) (1 trial)

oxycodone (oxycontin) (4 trials)

Drugs in Phase 2 Trials (2)

Key: Collegium Pharmaceutical, Inc. (0) Acquired (2)

clonidine (catapres) (3 trials)

morphine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Low Back Pain (Phase 3)

Overview

  • Highest Phase: None
  • # of Trials: 19
  • # of Trial APIs: 7